U-Blot® CTLA-4×PD-1 hIgG1 Reference Antibody (Cadbio)

Background:Cadonilimab antagonizes CTLA-4, preventing T cells from binding to its ligands, thereby alleviating immune suppression and promoting T cell activation. At the same time, Cadonilimab targets PD-1, blocking its interactions with PD-L1 and PD-L2, which relieves the inhibition on T cells and further enhances their anti-cancer activity. By simultaneously targeting both CTLA-4 and PD-1, Cadonilimab can activate T cells more comprehensively, significantly boosting the immune response against tumors.